摘要
受体酪氨酸激酶样孤儿受体1(ROR1)是一种在癌症生物学中具有新兴作用的蛋白,已被公认为治疗癌症的潜在靶点。近几年,无论是杂交瘤单克隆抗体还是基因工程抗体都已经被广泛地运用于肿瘤免疫治疗中,其技术也已经比较成熟。靶向ROR1抗体不仅具有特异性识别肿瘤抗原的特点,还具有高效、低毒杀死肿瘤细胞的功效。本文主要综述靶向ROR1肿瘤免疫治疗的研究进展。
Receptor tyrosine kinase-like orphan receptor 1(ROR1) is a new protein in cancer biology and has been recognized as a potential target for cancer therapy.In recent years,both monoclonal antibodies and genetic engineering antibodies have been widely used in tumor immunotherapy,and their techniques have been relatively mature.Targeted ROR1 antibodies not only have the characteristics of specific recognition of tumor antigens,but also have the effect of killing tumor cells with high efficiency and low toxicity.This article mainly reviews the advances in targeted ROR1 tumor immunotherapy.
作者
周琪
ZHOU Qi(School of Basic Medical Sciences,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2020年第9期1145-1149,共5页
Chinese Journal of Immunology
作者简介
周琪,女,在读硕士,主要从事中医药与肿瘤免疫方面的研究,E-mail:zhouqi@stu.cdutcm.edu.cn。
